170 related articles for article (PubMed ID: 16545878)
1. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response.
Geh JI; Bond SJ; Bentzen SM; Glynne-Jones R
Radiother Oncol; 2006 Mar; 78(3):236-44. PubMed ID: 16545878
[TBL] [Abstract][Full Text] [Related]
2. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer.
Geh JI; Crellin AM; Glynne-Jones R
Br J Surg; 2001 Mar; 88(3):338-56. PubMed ID: 11260097
[TBL] [Abstract][Full Text] [Related]
3. [Concurrent standard dose of cisplatin, paclitaxel, and radiotherapy followed by surgery in treatment of thoracic esophageal carcinoma].
Jiang YY; Wu SX; Zhang P; Xie CY; Wang J; Sun CC
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(31):2171-4. PubMed ID: 19080664
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).
Vestermark LW; Jacobsen A; Qvortrup C; Hansen F; Bisgaard C; Baatrup G; Rasmussen P; Pfeiffer P
Acta Oncol; 2008; 47(3):428-33. PubMed ID: 18348002
[TBL] [Abstract][Full Text] [Related]
5. [Neoadjuvant chemotherapy and chemoradiotherapy in the treatment of esophageal cancer].
Ando N; Ozawa S; Miki H; Suwa T; Kitajima M
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1878-85. PubMed ID: 7487116
[TBL] [Abstract][Full Text] [Related]
6. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB
Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881
[TBL] [Abstract][Full Text] [Related]
7. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
Miyoshi N; Yano M; Takachi K; Kishi K; Noura S; Eguchi H; Yamada T; Miyashiro I; Ohue M; Ohigashi H; Sasaki Y; Ishikawa O; Doki Y; Imaoka S
J Surg Oncol; 2009 Apr; 99(5):302-6. PubMed ID: 19170110
[TBL] [Abstract][Full Text] [Related]
8. Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer.
Welz S; Hehr T; Kollmannsberger C; Bokemeyer C; Belka C; Budach W
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1429-35. PubMed ID: 17692474
[TBL] [Abstract][Full Text] [Related]
9. [Neo-adjuvant chemoradiotherapy followed by surgery in treatment of advanced esophageal carcinoma].
Yang H; Fu JH; Hu Y; Lin P; Liu MZ; Li Q; Fang ZC; Hu YH
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(45):3182-5. PubMed ID: 19171088
[TBL] [Abstract][Full Text] [Related]
10. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.
Lim SB; Choi HS; Jeong SY; Kim DY; Jung KH; Hong YS; Chang HJ; Park JG
Ann Surg; 2008 Aug; 248(2):243-51. PubMed ID: 18650634
[TBL] [Abstract][Full Text] [Related]
11. Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG).
Teo PM; Leung SF; Tung SY; Zee B; Sham JS; Lee AW; Lau WH; Kwan WH; Leung TW; Chua D; Sze WM; Au JS; Yu KH; O SK; Kwong D; Yau TK; Law SC; Sze WK; Au G; Chan AT
Radiother Oncol; 2006 Apr; 79(1):27-33. PubMed ID: 16626829
[TBL] [Abstract][Full Text] [Related]
12. Prospective cohort comparison of neoadjuvant chemoradiotherapy versus chemotherapy in patients with oesophageal cancer.
Morgan MA; Lewis WG; Crosby TD; Escofet X; Roberts SA; Brewster AE; Harvard TJ; Clark GW
Br J Surg; 2007 Dec; 94(12):1509-14. PubMed ID: 17902093
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
[TBL] [Abstract][Full Text] [Related]
14. Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy.
Hsu FM; Lee YC; Lee JM; Hsu CH; Lin CC; Tsai YC; Wu JK; Cheng JC
Ann Surg Oncol; 2009 Jun; 16(6):1669-77. PubMed ID: 19267157
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer.
Ceelen W; Boterberg T; Pattyn P; van Eijkeren M; Gillardin JM; Demetter P; Smeets P; Van Damme N; Monsaert E; Peeters M
Ann Surg Oncol; 2007 Feb; 14(2):424-31. PubMed ID: 17096057
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
Kim DW; Blanke CD; Wu H; Shyr Y; Berlin J; Beauchamp RD; Chakravarthy B
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):397-404. PubMed ID: 17097833
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
Lindebjerg J; Spindler KL; Ploen J; Jakobsen A
Colorectal Dis; 2009 Mar; 11(3):264-9. PubMed ID: 18573119
[TBL] [Abstract][Full Text] [Related]
18. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.
Peeters ST; Heemsbergen WD; Koper PC; van Putten WL; Slot A; Dielwart MF; Bonfrer JM; Incrocci L; Lebesque JV
J Clin Oncol; 2006 May; 24(13):1990-6. PubMed ID: 16648499
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
[TBL] [Abstract][Full Text] [Related]
20. Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer.
Eifel PJ
Nat Clin Pract Oncol; 2006 May; 3(5):248-55. PubMed ID: 16683003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
